Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization

Experimental and Molecular Pathology

Volumn 97, Issue 3, 2014, Pages 411-424

  Fermento, María E ^a   Gandini, Norberto A ^a   Salomón, Débora G ^a   Ferronato, María J ^a   Vitale, Cristian A ^b   Arévalo, Julián ^c   López Romero, Alejandro ^d   Nuñez, Myriam ^e   Jung, Manfred ^f   Facchinetti, María M ^a   Curino, Alejandro C ^a  

^a Instituto de Investigaciones Bioquimicas Bahia Blanca   (Argentina)

^b UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^c Hospital Interzonal Dr Jose Penna   (Argentina)

^d Departamento de Hematología IACA   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Animal model; Breast cancer; Cell line; Human biopsies; P300

Indexed keywords

ACYLTRANSFERASE; E1A ASSOCIATED P300 PROTEIN; KI 67 ANTIGEN; PROTEIN BAX; EP300 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RISK; CELL COUNT; CELL INVASION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG METASTASIS; MIGRATION INHIBITION; MITOSIS INDEX; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL TIME; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CONFOCAL MICROSCOPY; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALIA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOPLASM; DISEASE MODELS, ANIMAL; E1A-ASSOCIATED P300 PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL;

EID: 84913588618     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.09.019     Document Type: Article

References (54)

1. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997, 89(7):1175-1184.
2. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279(49):51163-51171.
3. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384:641-643.
4. Bannister A.J., Miska E.A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. 2000, 57(8-9):1184-1192.
5. Bhandaru M., Ardekani G.S., Zhang G., Martinka M., McElwee K.J., Li G., Rotte A. A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer 2014, 14:398-409.
6. Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S.K., Civin C.I., Disteche C., Dubé I., Frischauf A.M., Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E. The translocation t (8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 1996, 14:33-41.
7. Bruzzone A., Vanzulli S.I., Soldati R., Giulianelli S., Lanari C., Luthy I.A. Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J. Cell. Physiol. 2009, 219:477-484.
8. Cebrat M., Kim C.M., Thompson P.R., Daugherty M., Cole P.A. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 2003, 11:3307-3313.
9. Chan H.M., La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 2001, 114(13):2363-2373.
10. Chen J., Halappanavar S., Th' ng J.P., Li Q. Ubiquitin-dependent distribution of the transcriptional coactivator p300 in cytoplasmic inclusion bodies. Epigenetics 2007, 2(2):92-99.
11. Chen Y., Shu W., Chen W., Wu Q., Liu H., Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol. 2007, 101:427-433.
12. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G., Balsano C., Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 2002, 9(1):175-186.
13. de Matos D.C., de Ribeiro L.C.A., Tansini A., Ferreira L.S., Placeres M.C.P., Colombo L.L., Carlos I.Z. Immunological response in mice bearing LM3 breast tumor undergoing pulchellin treatment. BMC Complement. Altern. Med. 2012, 12(107):2-6.
14. Debes J.D., Sebo T.J., Lohse C.M., Murphy L.M., Haugen D.A., Tindall D.J. p300 in prostate cancer proliferation and progression. Cancer Res. 2003, 63(22):7638-7640.
15. Eliseeva E.D., Valkov V., Jung M., Jung M.O. Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther. 2007, 6(9):2391-2398.
16. Facchinetti M.M., Gandini N.A., Fermento M.E., Sterin-Speziale N.B., Ji Y., Patel V., Gutkind J.S., Rivadulla M.G., Curino A.C. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 2010, 192(5):314-324.
17. a endometrial cancer cell line through the G protein-coupled estrogen receptor GPR30. Cell Signal. 2011, 23:1988-1996.
18. Gandini N.A., Fermento M.E., Salomón D.G., Blasco J., Patel V., Gutkind J.S., Molinolo A.A., Facchinetti M.M., Curino A.C. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. Exp. Mol. Pathol. 2012, 93:237-245.
19. Gandini N.A., Fermento M.E., Salomón D.G., Obiol D.J., Andrés N.A., Zenklusen J.C., Arévalo J., Blasco J., López Romero A., Facchinetti M.M., Curino A.C. Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma. Tumour Biol. 2014, 35:2803-2815.
20. Gao Y., Geng J., Hong X., Qi J., Teng Y., Yang Y., Qu D., Chen G. Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. Int. J. Clin. Exp. Pathol. 2014, 7(2):760-767.
21. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D., Ponder B.A., Kouzarides T., Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24(3):300-303.
22. Giles R.H., Peters D.J., Breuning M.H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998, 14(5):178-183.
23. Giordano A., Avantaggiati M.L. p300 and CBP: partners for life and death. J. Cell. Physiol. 1999, 181(2):218-230.
24. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14(13):1553-1577.
25. Green A.R., Burney C., Granger C.J., Paish E.C., El-Sheikh S., Rakha E.A., Powe D.G., Macmillan R.D., Ellis I.O., Stylianou E. The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res. Treat. 2008, 110(3):427-437.
26. Gueron G., De Siervi A., Ferrando M., Salierno M., De Luca P., Elguero B., Meiss R., Navone N., Vazquez E. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer Cells. Mol. Cancer Res. 2009, 7(11):1745-1755.
27. Han Y., Jeong H.M., Jin Y.H., Kim Y.J., Jeong H.G., Yeo C.Y., Lee K.Y. Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity. Biochem. Biophys. Res. Commun. 2009, 383:88-92.
28. Hudelist G., Czerwenka K., Kubista E., Marton E., Pischinger K., Singer C.F. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res. Treat. 2003, 78(2):193-204.
29. Huh J.W., Kim H.C., Kim S.H., Park Y.A., Cho Y.B., Yun S.H., Lee W.Y., Chun H.K. Prognostic impact of p300 expression in patients with colorectal cancer. J. Surg. Oncol. 2013, 108(6):374-377.
30. Ishihama K., Yamakawa M., Semba S., Takeda H., Kawata S., Kimura S., Kimura W. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J. Clin. Pathol. 2007, 60(11):1205-1210.
31. Iyer N.G., Ozdag H., Caldas C. p300/CBP and cancer. Oncogene 2004, 23:4225-4231.
32. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
33. Karamouzis M.V., Konstantinopoulos P.A., Papavassiliou A.G. Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res. 2007, 17:324-332.
34. Kurebayashi J., Otsuki T., Kunisue H., Tanaka K., Yamamoto S., Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators and corepressors in breast cancer. Clin. Cancer Res. 2000, 6:512-518.
35. Lanari C., Wargon V., Rojas P., Molinolo A.A. Antiprogestins in breast cancer treatment: are we ready?. Endocr. Relat. Cancer 2012, 9:35-50.
36. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., Wolffe A.P., Nakatani Y., Roeder R.G., Cole P.A. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 2000, 5:589-595.
37. Li M., Luo R.Z., Chen J.W., Cao Y., Lu J.B., He J.H., Wu Q.L., Cai M.Y. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J. Transl. Med. 2011, 9(5):2-11.
38. Li Y., Yang H.X., Luo R.Z., Zhang Y., Li M., Wang X., Jia W.H. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann. Thorac. Surg. 2011, 91:1531-1538.
39. Liao D., Yang H., Luo J. Targeting p300 for inhibiting triple negative breast cancer. Cancer Res. 2012, 72(8):S1.
40. Mackeh R., Lorin S., Ratier A., Mejdoubi-Charef N., Baillet A., Bruneel A., Hamaï A., Codogno P., Poüs C., Perdiz D. Reactive oxygen species, AMP-activated protein kinase and the transcription cofactor p300 regulate alpha-tubulin acetyltransferase-1 (αTAT-1/MEC-17)-dependent microtubule hyperacetylation during cell stress. J. Biol. Chem. 2014, 289(17):11816-11828.
41. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87(5):953-959.
42. Petit V., Boyer B., Lentz D., Turner C.E., Thiery J.P., Valles A.M. Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J. Cell Biol. 2000, 148:957-970.
43. Remmele W., Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8:138-140.
44. Rotte A., Bhandaru M., Cheng Y., Sjoestroem C., Martinka M., Li G. Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One 2013, 8(9):1-12.
45. Sebti S., Prébois C., Pérez-Gracia E., Bauvy C., Desmots F., Pirot N., Gongora C., Bach A.-S., Hubberstey A., Palissot V., Berchem G., Codogno P., Linares L., Liaudet-Coopman E., Pattingre S. BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(11):4115-4120.
46. Shi D., Pop M.S., Kulikov R., Love I.M., Kung A.L., Grossman S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(38):16275-16280.
47. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(18):10393-10398.
48. Syrjänen S., Naud P., Sarian L., Derchain S., Roteli-Martins C., Longatto-Filho A., Tatti S., Branca M., Erzen M., Serpa-Hammes L., Matos J., Arlindo F., Sakamoto-Maeda M., Costa S., Syrjänen K. p300 expression is related to high-risk human papillomavirus infections and severity of cervical intraepithelial neoplasia but not to viral or disease outcomes in a longitudinal setting. Int. J. Gynecol. Pathol. 2010, 29(2):135-145.
49. Tomita A., Towatari M., Tsuzuki S., Hayakawa F., Kosugi H., Tamai K., Miyazaki T., Kinoshita T., Saito H. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene 2000, 19(3):444-451.
50. Urtreger A.J., Ladeda V.E., Puricelli L.I., Rivelli A., Vidal M.C., Sacerdote de Lustig E., de Kier Bal, Joffé E. Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two murine mammary tumor cell lines. Int. J. Oncol. 1997, 11:489-496.
51. Vleugel M.M., Shvarts D., van der Wall E., van Diest P.J. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum. Pathol. 2006, 37(8):1085-1092.
52. Xiao X., Cai M., Chen J., Guan X., Kung H., Zeng Y., Xie D. High expression of p300 in human breast cancer correlates with tumor recurrence and predicts patients adverse prognosis. Chin. J. Cancer Res. 2011, 23(3):3-9.
53. Yang H., Pinello C.E., Luo J., Li D., Wang Y., Zhao L.Y., Jahn S.C., Saldanha S.A., Planck J., Geary K.R., Ma H., Law B.K., Roush W.R., Hodder P., Liao D. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol. Cancer Ther. 2013, 2(5):610-620.
54. Zhou J., Zhan S., Tan W., Cheng R., Gong H., Zhu Q. p300 binds to and acetylates MTA2 to promote colorectal cancer cells growth. Biochem. Biophys. Res. Commun. 2014, 444:387-390.